Glaucoma diagnostic platform, will provide early detection of Glaucoma by means of an affordable, easy-to-use, point-of-care test, yielding a Glaucoma Risk Score within a few minutes.

At m-lab, we are committed to commercialize a Glaucoma diagnostic platform that will provide the general population easy, affordable and widespread access to disease detection and early treatment initiation. We foresee a yearly test at below €20.

We expect the launch of the diagnostic platform within 2 years.  In parallel, we are continuously developing our therapeutic antibody program.